Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVS451
- Development stage
- Phase 1
- Lead developer
- Sinopharm Zhongsheng Biotechnology Research Institute
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
NVS451 is a recombinant fusion protein under development as an injectable therapy for moderate to severe plaque psoriasis. It is being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy in both healthy volunteers and patients with moderate to severe plaque psoriasis. The precise mechanism of action has not been disclosed publicly as of June 2025. The drug is administered subcutaneously and was initially developed by Sinopharm Zhongsheng Biotechnology Research Institute.
- Other names
- NVS451 fusion proteinNVS-451 fusion proteinNVS 451 fusion protein
Beyond the preview
Go deeper on NVS451.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVS451.